Promotion of Phynova Joint & Muscle Pain Relief Tablets (Sigesbeckia extract) on website
Published 9 June 2021
© Crown copyright 2021
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/advertising-investigations-march-2021/promotion-of-phynova-joint-muscle-pain-relief-tablets-sigesbeckia-extract-on-website
SUMMARY REPORT FOR PUBLICATION
March 2021 Promotion of Phynova Joint & Muscle Pain Relief Tablets (Sigesbeckia extract) on website
The MHRA reviewed information on Phynova Joint & Muscle Pain Relief Tablets on their website. The MHRA was concerned that the website included advice provided by a named doctor in a form that appeared to make a recommendation for Sigesbeckia extract / Phynova Joint & Muscle Pain Relief. Regulation 289 prohibits the inclusion in advertising of a recommendation from a healthcare professional to use the specific medicine being advertised. The product is registered under the Traditional Herbal Registration (THR) Scheme on the basis of traditional use only and without evidence of efficacy.
The MHRA contacted the registration holder, Phynova, who removed the recommendations by the healthcare professional for the use of Sigesbeckia. They also ensured that claims for the use of the product are set in the context that the registration of the product is based solely on evidence of traditional use.